Source comparison
MK-677 60s Age-Specific Protocol: Comparison
Starting Dose 12.5–25mg daily 6.25mg daily for 14 days Lower starting dose mitigates glucose spike risk and allows adaptation to appetite changes in populations with baseline insulin resistance Maintenance Dose 20–25mg daily 12.5mg daily (ceiling) Receptor sat
This comparison does not assign a generated winner or score.
- Starting Dose
- 12.5–25mg daily
- 6.25mg daily for 14 days
- Lower starting dose mitigates glucose spike risk and allows adaptation to appetite changes in populations with baseline insulin resistance
- Maintenance Dose
- 20–25mg daily
- 12.5mg daily (ceiling)
- Receptor saturation limits additional GH release above 12.5mg in older adults; higher doses increase adverse effects without proportional benefit
- Dosing Timing
- Morning or evening
- Evening only (8–9 PM)
- Evening administration aligns with circadian GH pulse and reduces daytime hyperphagia driven by ghrelin receptor activation
- Glucose Monitoring
- Optional
- Fasting glucose every 3 days (weeks 1–8), HbA1c at baseline and week 12
- Mandatory due to 30–50% higher baseline insulin resistance in adults >60; early detection prevents progression to prediabetes
- Contraindications
- Active cancer, uncontrolled diabetes
- Active cancer, HbA1c >5.7% without glucose-lowering co-therapy, eGFR <45 mL/min
- Stricter thresholds reflect age-related decline in renal clearance and heightened cancer risk in older populations
- Cycle Length
- Continuous or 5-day-on / 2-day-off
- Continuous preferred; assess every 12 weeks
- Intermittent dosing reduces compliance and disrupts GH pulsatility restoration; continuous use with quarterly reassessment is safer